AMD 3465 (hydrobromide) – 25 mg

Brand:
Cayman
CAS:
185991-07-5
Storage:
-20
UN-No:
Non-Hazardous - /

C-X-C chemokine receptor type 4 is a receptor for the stromal cell-derived factor-1 which is designated as chemokine ligand 12 (CXCL12). It is involved in cell progression, hematopoiesis, cancer, HIV entry, and rheumatoid arthritis.{15449,16830,21624} AMD 3465 blocks the cell surface binding of CXCL12 with an IC50 value of 18 nM.{22141} It inhibits CXCL12-induced calcium mobilization (IC50 = 4 nM) and at 6,250 nM completely blocks CXCL12-induced chemotaxis of SupT1 cells.{22141} AMD 3465 is active against various HIV strains with IC50 values ranging from 6 to 12 nM.{22141} It dose dependently inhibits eosinophil recruitment during type-2 granuloma formation and interferes with primary and secondary T-cell activation events in lymphoid tissue.{22142} At 50 μg/day, AMD 3465 blocks tumor growth and prevents CXCL12-induced cAMP suppression in xenograft models of medulloblastoma and glioblastoma.{22140}  

 

Available on backorder

SKU: 11959 - 25 mg Category:

Description

Blocks the cell surface binding of the CXCR4 ligand CXCL12 (IC50 = 18 nM), inhibits calcium mobilization (IC50 = 4 nM), and (at 6,250 nM) completely blocks chemotaxis of SupT1 cells; active against various HIV strains (IC50s = 6-12 nM)


Formal name: N-[[4-(1,4,8,11-tetraazacyclotetradec-1-ylmethyl)phenyl]methyl]-2-pyridinemethanamine, hexahydrobromide

Synonyms: 

Molecular weight: 896.1

CAS: 185991-07-5

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cancer|Cell Migration & Metastasis||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Infectious Disease|Viral Diseases|HIV & AIDS